PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LosePRTA / S&P 0.72% / 15.20% |
WinPRTA / S&P 427.32% / 15.00% |
LosePRTA / S&P -85.08% / 50.40% |
| 2026-Q12/3 |
WinPRTA / S&P 1.78% / -4.33% |
LosePRTA / S&P -57.99% / 11.30% |
WinPRTA / S&P 36.23% / 27.70% |
| 2025-Q41/3 |
LosePRTA / S&P -2.15% / 2.65% |
LosePRTA / S&P -92.83% / 9.00% |
WinPRTA / S&P 98.25% / 13.40% |
| 2025-Q32/3 |
WinPRTA / S&P 60.79% / 8.12% |
LosePRTA / S&P -91.16% / 4.61% |
WinPRTA / S&P 110.08% / 13.45% |
| 2025-Q21/3 |
LosePRTA / S&P -50.95% / 10.94% |
LosePRTA / S&P -95.24% / 4.83% |
WinPRTA / S&P 463.00% / 10.63% |
| 2025-Q11/3 |
LosePRTA / S&P -10.65% / -4.27% |
WinPRTA / S&P 54.55% / 4.98% |
LosePRTA / S&P -36.31% / 10.57% |
| 2024-Q41/3 |
LosePRTA / S&P -17.21% / 2.41% |
WinPRTA / S&P 47.92% / 5.25% |
LosePRTA / S&P -18.21% / 6.15% |
| 2024-Q31/3 |
LosePRTA / S&P -18.94% / 5.89% |
LosePRTA / S&P -5.41% / 5.89% |
WinPRTA / S&P 79.71% / 6.11% |
| 2024-Q21/3 |
LosePRTA / S&P -16.67% / 4.28% |
WinPRTA / S&P 276.98% / 5.38% |
LosePRTA / S&P -63.37% / 5.12% |
| 2024-Q12/3 |
LosePRTA / S&P -31.84% / 10.56% |
WinPRTA / S&P 62.51% / 5.71% |
WinPRTA / S&P 25.97% / 5.59% |
| 2023-Q42/3 |
LosePRTA / S&P -24.68% / 11.69% |
WinPRTA / S&P 69.50% / 6.81% |
WinPRTA / S&P 13.36% / 7.78% |
| 2023-Q31/3 |
LosePRTA / S&P -29.34% / -3.27% |
WinPRTA / S&P 2635.29% / 7.52% |
LosePRTA / S&P -59.05% / -5.03% |
| 2023-Q22/3 |
WinPRTA / S&P 40.87% / 8.74% |
LosePRTA / S&P -59.65% / 9.50% |
WinPRTA / S&P 911.11% / -8.57% |
| 2023-Q10/3 |
LosePRTA / S&P -19.55% / 7.50% |
LosePRTA / S&P -72.75% / 10.77% |
LosePRTA / S&P -316.81% / -15.69% |
| 2022-Q40/3 |
LosePRTA / S&P -0.63% / 7.56% |
LosePRTA / S&P -73.13% / 11.88% |
LosePRTA / S&P -333.02% / -17.99% |
| 2022-Q31/3 |
WinPRTA / S&P 123.31% / -4.88% |
LosePRTA / S&P -97.42% / 13.47% |
LosePRTA / S&P -424.04% / -1.41% |
| 2022-Q21/3 |
LosePRTA / S&P -25.76% / -16.10% |
WinPRTA / S&P 135.09% / 13.71% |
LosePRTA / S&P -85.48% / 11.04% |
| 2022-Q11/3 |
LosePRTA / S&P -25.97% / -4.60% |
WinPRTA / S&P 23015.83% / 15.97% |
LosePRTA / S&P -138.39% / 42.23% |
| 2021-Q41/3 |
LosePRTA / S&P -30.65% / 11.03% |
WinPRTA / S&P 23414.30% / 15.00% |
LosePRTA / S&P PRTA unavailable / 96.40% |
| 2021-Q32/3 |
WinPRTA / S&P 38.55% / 0.58% |
WinPRTA / S&P 26570.89% / 10.77% |
LosePRTA / S&P PRTA unavailable / 69.42% |
| 2021-Q22/3 |
WinPRTA / S&P 104.66% / 8.55% |
WinPRTA / S&P 7522.08% / 6.58% |
LosePRTA / S&P PRTA unavailable / 51.81% |
| 2021-Q12/3 |
WinPRTA / S&P 109.16% / 6.17% |
WinPRTA / S&P 13.39% / -1.06% |
LosePRTA / S&P PRTA unavailable / 7.39% |
| 2020-Q42/3 |
WinPRTA / S&P 20.22% / 12.15% |
WinPRTA / S&P 4.79% / -3.72% |
LosePRTA / S&P PRTA unavailable / -33.42% |
| 2020-Q31/3 |
LosePRTA / S&P -4.49% / 8.93% |
WinPRTA / S&P -0.40% / -2.04% |
LosePRTA / S&P PRTA unavailable / -27.10% |
| 2020-Q20/3 |
LosePRTA / S&P -2.24% / 20.54% |
LosePRTA / S&P -0.62% / -0.46% |
LosePRTA / S&P PRTA unavailable / -27.11% |
| 2020-Q10/3 |
LosePRTA / S&P -32.41% / -19.60% |
LosePRTA / S&P -15.86% / 3.47% |
LosePRTA / S&P PRTA unavailable / -14.75% |
| 2019-Q41/3 |
WinPRTA / S&P 101.91% / 9.07% |
LosePRTA / S&P -14.76% / 5.36% |
LosePRTA / S&P PRTA unavailable / 2.99% |
| 2019-Q30/3 |
LosePRTA / S&P -25.83% / 1.70% |
LosePRTA / S&P -24.04% / 5.02% |
LosePRTA / S&P PRTA unavailable / 0.21% |
| 2019-Q20/3 |
LosePRTA / S&P -12.86% / 4.30% |
LosePRTA / S&P -15.93% / 6.64% |
LosePRTA / S&P PRTA unavailable / 8.65% |
| 2019-Q11/3 |
WinPRTA / S&P 17.77% / 13.65% |
LosePRTA / S&P -96.67% / 8.12% |
LosePRTA / S&P PRTA unavailable / 14.29% |
| 2018-Q40/3 |
LosePRTA / S&P -21.25% / -13.52% |
LosePRTA / S&P -96.53% / 9.05% |
LosePRTA / S&P PRTA unavailable / 18.23% |
| 2018-Q30/3 |
LosePRTA / S&P -10.29% / 7.71% |
LosePRTA / S&P -96.39% / 10.21% |
LosePRTA / S&P PRTA unavailable / 19.06% |
| 2018-Q20/3 |
LosePRTA / S&P -60.28% / 3.43% |
LosePRTA / S&P -96.53% / 9.03% |
LosePRTA / S&P PRTA unavailable / 14.46% |
| 2018-Q11/3 |
LosePRTA / S&P -2.08% / -0.76% |
WinPRTA / S&P 2520.31% / 7.68% |
LosePRTA / S&P PRTA unavailable / 12.46% |
| 2017-Q41/3 |
LosePRTA / S&P -42.12% / 6.64% |
WinPRTA / S&P 2508.44% / 7.03% |
LosePRTA / S&P PRTA unavailable / 13.82% |
| 2017-Q32/3 |
WinPRTA / S&P 19.68% / 4.48% |
WinPRTA / S&P 2205.71% / 5.68% |
LosePRTA / S&P PRTA unavailable / 17.57% |
| 2017-Q21/3 |
LosePRTA / S&P -2.99% / 3.09% |
WinPRTA / S&P 1963.57% / 4.83% |
LosePRTA / S&P PRTA unavailable / 17.74% |
| 2017-Q11/3 |
WinPRTA / S&P 13.42% / 6.07% |
LosePRTA / S&P -17.98% / 3.67% |
LosePRTA / S&P PRTA unavailable / 13.32% |
| 2016-Q40/3 |
LosePRTA / S&P -17.98% / 3.82% |
LosePRTA / S&P -34.35% / 2.09% |
LosePRTA / S&P PRTA unavailable / 7.05% |
| 2016-Q31/3 |
WinPRTA / S&P 71.54% / 3.85% |
LosePRTA / S&P -64.05% / 0.20% |
LosePRTA / S&P PRTA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 10.85% | 20.78% |
| Annualized return | 10.85% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PRTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -86.99% | 83.14% |
| Annualized return | -33.50% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PRTA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.59% | 319.30% |
| Annualized return | -16.04% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |